Adaptive Biotechnologies Corporation (ADPT)
Adaptive Biotechnologies Corporation (ADPT) is a healthcare company (diagnostics & research) based in the United States. The share price is $28.41, up 1.94% on the day, which values the company at $4.6B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.
Key facts
- Share price
- $28.41+1.94% today
- Market value
- $4.6B
- Funk Score
- 43/100
- Against its own history
- Well above its usual priceusual price $10.66
- 200-week average
- $10.36174% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Adaptive Biotechnologies Corporation in more detail
ADPT trades at -852.4× next year's expected earnings, 15.4× sales. Measured against its own history, the price is 166% above what its usual multiples would imply ($10.66) — well above its usual price. It sits 174% above its 200-week average of $10.36.
Over the last five fiscal years Adaptive Biotechnologies Corporation has compounded revenue 23.0% a year. Its Funk Score is 43 out of 100 (financial strength 6.7, profitability 2.0, growth 8.5, value 0.0, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Thin interest cover.
3 of the superinvestors tracked here hold ADPT, including Andreas Halvorsen (1.8% of the portfolio), Cathie Wood (0.3% of the portfolio), Polen Capital team (0.0% of the portfolio).
Superinvestors holding ADPT
3 of the investors tracked here report a position in their latest 13F filing.
- Andreas Halvorsen Viking Global Investors1.83% of portfolio · $643.4M · Q2 2026
- Cathie Wood ARK Invest0.32% of portfolio · $55.5M · trimmed · Q3 2026
- Polen Capital team Polen Capital Management0.04% of portfolio · $4.1M · added · Q3 2026
Health Care companies of similar size
- Merit Medical SystemsMMSI
- Edgewise TherapeuticsEWTX
- LivaNovaLIVN
- Ionis PharmaceuticalsIONS
- Dianthus TherapeuticsDNTH
- MiniMed GroupMMED
- HeartflowHTFL
- CRISPR TherapeuticsCRSP
- Travere TherapeuticsTVTX
- Option Care HealthOPCH
- Legend BiotechLEGN
- Definium TherapeuticsDFTX
Side by side:ADPT vs MMED (Adaptive Biotechnologies Corporation vs MiniMed Group)ADPT vs HTFL (Adaptive Biotechnologies Corporation vs Heartflow)ADPT vs CRSP (Adaptive Biotechnologies Corporation vs CRISPR Therapeutics)ADPT vs DNTH (Adaptive Biotechnologies Corporation vs Dianthus Therapeutics)ADPT vs TVTX (Adaptive Biotechnologies Corporation vs Travere Therapeutics)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Adaptive Biotechnologies Corporation (ADPT): questions and answers
What is Adaptive Biotechnologies Corporation's market cap?
Adaptive Biotechnologies Corporation is valued at $4.6B at a share price of $28.41.
Is ADPT overvalued or undervalued?
Against its own history, ADPT is well above its usual price: the price is 166% above the $10.66 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ADPT above its 200-week moving average?
Yes. ADPT is 174.2% above its 200-week average of $10.36. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Adaptive Biotechnologies Corporation growing?
Over the last five fiscal years Adaptive Biotechnologies Corporation's revenue grew 23.0% a year.
Does ADPT pay a dividend?
Adaptive Biotechnologies Corporation does not currently pay a regular dividend.
Which famous investors own ADPT?
In their latest quarterly filings, Andreas Halvorsen (1.8% of the portfolio), Cathie Wood (0.3% of the portfolio), Polen Capital team (0.0% of the portfolio) hold ADPT. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Adaptive Biotechnologies Corporation (ADPT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ADPT
Underlying data: Yahoo Finance; company filings with the SEC.